Latest News and Press Releases

Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Timetable update for the proposed Subscription and Placing Oxford, UK, and Cambridge, MA, US, 19 December 2019 - Summit...

Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2019 on 17 December 2019 Oxford, UK, and...

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR INTO ANY JURISDICTION IN...

THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress Oxford, UK, and Cambridge, MA, US, 6 November...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Therapeutics Recognises C. difficile Awareness Month Company to Highlight Potential of Phase 3 Precision Antibiotic Ridinilazole...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at the 2019 BIO Investor Forum Oxford, UK, and Cambridge, MA, US, 16 October 2019 – Summit...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Director Change Oxford, UK, and Cambridge, MA, US, 11 October 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) a leader in new mechanism...

Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended 31 July 2019 ...